The mouse mAb TP25.99 (4) is among the few mAb (5, 6) reacting with both ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains. Whether this unusual reactivity pattern reflects the sharing of an antigenic determinant between ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains or the recognition by mAb TP25.99 of two distinct determinants is not known. A previous study has mapped the conformational determinant recognized by mAb TP25.99 on ␤ 2 m-associated HLA class I heavy chains to amino acid residues 184 -199 in their ␣3 domain (7). In contrast, the linear determinant recognized by mAb TP25.99 on ␤ 2 m-free HLA class I heavy chains has not been mapped. In addition, the distribution of the determinant(s) recognized by mAb TP25.99 on HLA class I allospecificities has not been investigated.
L ike their counterparts in other animal species, HLA class I Ags are composed of two noncovalently associated subunits; the monomorphic polypeptide ␤ 2 -microglobulin (␤ 2 m) 3 and a highly polymorphic transmembrane heavy chain encoded by the HLA-A, -B, and -C loci (1) . The association of HLA class I heavy chains with ␤ 2 m drastically modifies their conformation. The resulting changes in their antigenic profile (2, 3) account for the selective reactivity of polyclonal and mAbs with either ␤ 2 m-free or ␤ 2 m-associated HLA class I heavy chains.
The mouse mAb TP25.99 (4) is among the few mAb (5, 6) reacting with both ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains. Whether this unusual reactivity pattern reflects the sharing of an antigenic determinant between ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains or the recognition by mAb TP25.99 of two distinct determinants is not known. A previous study has mapped the conformational determinant recognized by mAb TP25.99 on ␤ 2 m-associated HLA class I heavy chains to amino acid residues 184 -199 in their ␣3 domain (7) . In contrast, the linear determinant recognized by mAb TP25.99 on ␤ 2 m-free HLA class I heavy chains has not been mapped. In addition, the distribution of the determinant(s) recognized by mAb TP25.99 on HLA class I allospecificities has not been investigated.
In the present study, we have characterized the distribution of the determinant(s) recognized by mAb TP25.99 on ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains. Furthermore, using immunochemical methods and phage display peptide libraries, we have mapped the conformational and the linear determinants recognized by mAb TP25.99 on HLA class I heavy chains. This information contributes to our understanding of the structural relatedness of distinct antigenic determinants defined by a mAb and of the conformational changes in HLA class I heavy chains induced by their association with ␤ 2 m.
Materials and Methods
mAbs and conventional antisera mAb TP25.99 is secreted by a hybridoma generated by fusing the nonsecretor myeloma cells P3-X63-Ag8.653 with splenocytes from a BALB/c mouse immunized with multiple injections of IFN-␥-treated cultured human melanoma cells Colo 38. mAb W6/32 to a monomorphic determinant expressed on ␤ 2 m-associated HLA-A, -B, and -C heavy chains (8) , mAb HC-10 to a determinant preferentially expressed on ␤ 2 m-free HLA-B and -C heavy chains (9) , mAb CR11-351 to a conformational determinant shared by HLA-A2 and A28 Ags (10), anti-HLA-DR, DQ, DP mAb LGII-612.14 (11), rabbit anti-␤ 2 m-free HLA class I heavy chain serum R 5996-4 (12) , and rabbit anti-HLA class I heavy chain serum (13) were developed and characterized as previously described. mAb were purified from ascitic fluid by sequential precipitation with caprylic acid and ammonium sulfate (14) . The purity of the mAb preparations was assessed by SDS-PAGE. Biotinylation of mAb was performed using NHS-LC-Biotin (Pierce, Rockford, IL) according to the manufacturer's instructions. mAb were radiolabeled with 125 I using the Iodogen method (15) .
Affinity purified rabbit anti-mouse (3) IgG (heavy chain ϩ light chain) Abs and HRP-conjugated goat anti-mouse (GAM-HRP) Abs were purchased from Jackson ImmunoResearch (West Grove, PA).
Technologies, Grand Island, NY) supplemented with 10% serum plus supplement (BioWhittaker, Walkersville, MD) and 2 mM L-glutamine (Life Technologies). All cell lines were cultured at 37°C in a 5% CO 2 atmosphere. Cell lysates were prepared as described (16) .
Phage display peptide libraries
Phage display peptide libraries X 15 and LX-8 (XCX 8 CX) displaying 15 aa, random, linear peptides and 8 aa random, disulfide constrained peptides, respectively, were kindly provided by Dr. J. K. Scott (Simon Fraser University, Burnaby, British Columbia, Canada). The peptide libraries were constructed using bacteriophage vector f88.4 and had random peptide inserts at the N terminus of the synthetic pVIII major coat protein. Both peptide libraries were re-amplified in Escherichia coli host K91kan from an aliquot of phage stock provided. Phage particles were purified by two precipitations with polyethylene glycol/NaCl (16.7%/3.3 M) and resuspended in 10 ml TBS 50 (50 mM Tris-HCl (pH 7.5), 150 mM NaCl) giving a titer of 5 ϫ 10 12 transducing U/ml.
Synthetic peptides
The amino acid sequence of the synthetic peptides used in the present study is shown in Table I 
Coating of plates with Ags
Polyvinylchloride, U-bottom, 96-well microtiter plates (Titertek, Huntsville, AL) coated with HLA class I Ags captured from cell lysates by anti-HLA class I mAb were prepared as described elsewhere (16) . Plates were coated with synthetic peptides by adding to each well 100 l of a 0.25% glutaraldehyde cross-linked synthetic peptide solution at concentrations varying from 1 to 50 M. Following a 2-h incubation at 37°C and washing of the plate with TBS 10 (10 mM Tris-HCl (pH 7.5), 150 mM NaCl), wells were blocked for 1 h at 37°C with TBS 10 containing 2% BSA.
Binding assays
The assay to measure the immunoreactive fraction of radiolabeled mAb (17) , the binding assay with 125 I-labeled mAb (18) , and the Scatchard plot analysis of the binding of radiolabeled mAb to cells (19) were performed as described elsewhere.
The inhibition assay to determine the ability of synthetic peptides to inhibit the binding of mAb to HLA class I Ags or to a synthetic peptide was performed by mixing varying amounts of synthetic peptide solution with unconjugated or biotinylated mAb. mAb were used at concentrations giving absorbance measured at 490 nm (A 490 ) ϭ 1.0 in the absence of inhibitors. Following an overnight incubation at 4°C, the mixture was transferred to plates coated with HLA class I Ags or a synthetic peptide, and incubation was continued for an additional hour at room temperature. Following washing of the plates with TBS-T (TBS 10 containing 0.05% Tween 20) , 100 l of a 1:2,500 dilution of HRP-conjugated streptavidin (SA-HRP; Pierce) or of a 1:10,000 dilution of a GAM-HRP solution were added to each well and incubation was continued for an additional hour at room temperature. The reaction was developed using an o-phenylenediamine-H 2 O 2 substrate solution and terminated by the addition of 4 N H 2 SO 4 . Results are expressed as the percent of inhibition calculated using the following formula: % inhibition ϭ ((A 490 in the absence of inhibitor-A 490 in the presence of inhibitor)/A 490 in the absence of inhibitor) ϫ 100. Western blot analysis was performed as described by Towbin et al. (22) with minor modifications. Briefly, a 1% Nonidet P-40 extract of cultured cells was electrophoresed on a 12% polyacrylamide gel in the presence of SDS. Separated proteins were then transferred to an Immobilon-P transfer membrane (Millipore, Bedford, MA). Following blocking of the membrane for 1 h at room temperature with PBS supplemented with 5% skimmed milk powder, filters were incubated with 2 ϫ 10 5 cpm/ml 125 I-labeled mAb for 4 h at room temperature. After three washes with PBS containing 0.05% Tween 20, filters were dried and autoradiographed at Ϫ70°C using Hyperfilm-MP (Amersham). One-dimensional isoelectric focusing (1D-IEF) of HLA class I Ags using detergent-solubilized B lymphoblastoid cell line lysates was performed as described by Neefjes et al. (13) , followed by immunoblotting with mAb TP25.99 or with rabbit anti-HLA class I heavy chain antiserum (23) .
Immunochemical methods

Panning of peptide libraries with mAb TP25.99
Micropanning of amplified peptide libraries X 15 and LX-8 with biotinylated mAb TP25.99 was performed in 96-well microtiter plates (Falcon; Becton Dickinson, Lincoln Park, NJ) as described (24) . The first round of panning was performed using 1 ϫ 10 12 phage particles in TBS 50 and 1 g biotinylated mAb TP25.99 per well. The subsequent three rounds of selection were conducted using 1 ϫ 10 10 phage particles and 0.1 g biotinylated mAb per well. Eluted phages from each round of panning were amplified in K91kan cells prepared as described by Smith and Scott (25) and used as input for the next round of panning. Phage enrichment, (i.e., percent yield, defined as the percent of eluted phages/input phages) at the end of panning was determined by spot titering on NZY plates containing 20 g/ml tetracycline, as described by Smith and Scott (25) .
Immunoscreening of peptide libraries with mAb
The immunoscreening assay to test the reactivity of random phage clones with mAb was performed as described by Valadon and Scharff (26) with minor modifications. Briefly, nitrocellulose filter (Protran; Schleicher and Schuell, Keene, NH) lifts from plates containing colonies were probed with 5 g/ml mAb and 2 g/ml biotinylated rabbit anti-mouse IgG (heavy chain ϩ light chain) Abs in TNT buffer (TBS-T containing 20% FBS). Following an overnight incubation at 4°C, filters were washed with TBS 10 containing 1 mg/ml BSA, and incubated with a 1:2500 dilution of a SA-HRP solution in TNT buffer. Following three washes with TBS 10 containing 1 mg/ml BSA, filters were developed using enhanced chemiluminescence (Amersham).
Nucleotide sequence analysis of phage inserts
Nucleotide sequence of peptide inserts was determined by the dideoxynucleotide chain termination method (27) as described by Bonnycastle et al. (24) with the following modifications. Purified phages were prepared from the supernatant of individual clones by polyethylene glycol/ NaCl precipitation. Sequencing reactions were performed with 2 ϫ 10 11 phage particles in microtiter wells (GeNunc; Nunc, Roskilde, Denmark) using the SEQUENASE kit (version 2.0, United State Biochemicals, Cleveland, OH) and 32 P-end-labeled f88.4 sequencing primer, 5Ј-CTGAAGAGAGTCAAAAGC-3Ј. The distribution of the conformational determinant recognized by mAb TP25.99 on ␤ 2 m-associated HLA class I allospecificities was analyzed by 1D-IEF analysis of HLA class I Ags immunoprecipitated from Triton X-114 detergent-solubilized lysates of B lymphoid cell lines (data not shown). All the known HLA-A and HLA-B allospecificities were detected in the immunoprecipitates with mAb TP25.99. The intensity of bands corresponding to HLA-A2, A10, A19, and A28 alleles were much weaker than those of the other HLA class I alleles. The distribution of the determinant recognized by mAb TP25.99 on ␤ 2 m-free HLA class I heavy chains encoded by A and B loci was investigated by testing its reactivity in Western blotting with HLA class I allospecificities solubilized from B lymphoid cell lines and separated by 1D-IEF (Fig. 4) . mAb TP25.99 reacted with all the known ␤ 2 m-free HLA-B allospecificities except HLA-B73 and with Ͻ50% of all the known ␤ 2 m-free HLA-A allospecificities. The latter include HLA-A1, A3, A9, A11, and A30 alleles. Correlation between the differential reactivity with mAb TP25.99 of HLA class I allospecificities and the amino acid sequence of their heavy chain ␣3 domain is shown in Table I . This data suggests that changes in amino acid residues P193, I194, G207, A245, A246, and E253 are associated with lack of reactivity of mAb TP25.99 with ␤ 2 m-free HLA class I heavy chains. This information together with mapping of the linear determinant recognized by 35 S]methionine-labeled LKT13 cells was immunodepleted with mAb TP25.99 and anti-HLA class I mAb W6/32. Each immunodepleted extract was immunoprecipitated with insolubilized mAb TP25.99 and mAb W6/32. Ags were then eluted and analyzed by SDS-PAGE in a 12% polyacrylamide gel in the presence of 2-ME. Gels were then processed for fluorography. Immunodepletion and immunoprecipitation with anti-HLA class II mAb LGII-612.14 was used as a specificity control. 3) and with rabbit serum R 5996-4 (lanes 4 -6). Each immunodepleted extract was immunoprecipitated with insolubilized mAb TP25. 99 (lanes 1, 4, and 7) and rabbit serum R 5996-4 (lanes 2, 5, and 8). Ags were eluted and analyzed by SDS-PAGE in a 12% polyacrylamide gel in the presence of 2-ME. Gels were then processed for fluorography. Immunodepletion (lanes 7-9) and immunoprecipitation  (lanes 3, 6, and 9 ) with anti-HLA class II mAb LGII-612.14 was used as a specificity control. mAb TP25.99 on ␤ 2 m-free HLA class I heavy chains (to be described in a later section) suggests that the two alanine residues at positions 245 and 246 and especially the glutamic acid residue at position 253 play a crucial role in the expression of the determinant recognized by mAb TP25.99 on ␤ 2 m-free HLA class I heavy chains. Thus the substitution of A and E by V and Q at positions 245 and 253, respectively, as in the HLA-A68 allospecificity; the substitution of A and E by S and Q at positions 246 and 253, respectively, as in the HLA-A10, A29, A31, A32, A33, A34, A66, and A74 allospecificities; or the substitution of E by Q at position 253 as in the HLA-A2, A69, and B73 allospecificities results in loss of the expression of the determinant recognized by mAb TP25.99.
Results
Reactivity
These results suggest that the conformational and linear determinants are located on distinct regions of the HLA class I heavy chain ␣3 domain. Furthermore the determinant recognized by mAb TP25.99 on ␤ 2 m-free HLA class I heavy chains has a differential distribution on HLA class I allospecificities.
Selection and screening of phage-displayed peptides binding to mAb TP25.99
To identify the determinant(s) recognized by mAb TP25.99 on ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains, phagedisplayed peptide clones were isolated by panning the random phage-displayed peptide libraries, LX-8 and X 15 (24) with mAb TP25.99. Four rounds of panning of the LX-8 and X 15 libraries resulted in an enrichment of 0.44% and 0.92%, respectively. Immunological screening of colonies at the end of the fourth round of panning detected reactivity of mAb TP25.99 with 35% and 70% of the colonies isolated from the LX-8 and X 15 libraries, respectively.
Amino acid sequence homology of peptides identified by mAb TP25.99 with HLA class I heavy chains
Nucleotide sequence analysis identified three distinct sequences in the peptides expressed by seven randomly selected clones among those isolated from the LX-8 library. Four, two, and one clone had peptide inserts with the sequences QCTNFISDHECH, SCDG FYTGPACM, and QCVETWNRIECK, respectively (Table II) . In contrast, only the sequence IDPVGWGNERTFQVP was found in the peptides expressed by eight randomly selected clones sequenced from the X 15 library. The peptides expressed by the clones isolated from the two libraries display homology in their amino acid sequence with HLA-A, -B, and -C heavy chain ␣3 domain. The ISDHE sequence in the peptide most frequently expressed in clones isolated from the LX-8 library is present at positions 194 -198 in HLA-B and -C heavy chain ␣3 domains (Fig. 5) . These amino acids with the exception of I are also present at positions 195-198 in HLA-A heavy chain ␣3 domains. Furthermore, the GFY sequence in the peptides expressed by two clones isolated from the LX-8 library is present at positions 207-209 in the HLA-B and -C heavy chain ␣3 domains and the amino acids P and A are present at positions 210 and 211 in the HLA-A, -B, and -C heavy chain ␣3 domain. Additionally, the VET sequence in the peptide expressed by one clone isolated from the LX-8 library is present at positions 231-233 in the HLA-A, -B, and -C heavy chain ␣3 domains.
Among the three phage-displayed peptides isolated from the LX-8 library, the phage expressing the peptide insert SCDGFYT GPACM reacted to a lower extent with mAb TP25.99 than the phages expressing the peptide inserts QCTNFISDHECH and QCVETWNRIECK. The latter two did not differ in their reactivity with mAb TP25.99 (Table II) . The residues ISDHE are likely to mediate the binding of mAb TP25.99 to ␤ 2 m-associated HLA class I heavy chains, because the three dimensional structure of the HLA class I Ag reveals that these residues are exposed on the ␤ 2 massociated HLA class I heavy chain complex. In contrast, the residues GFYPA and VET are not accessible for binding to mAb TP25.99 when HLA class I heavy chains are associated with ␤ 2 m. Thus, these residues are less likely to be involved in the binding of mAb TP25.99 to ␤ 2 m-associated HLA class I heavy chains.
The RTFQ sequence in the peptide expressed by the clones isolated from the X 15 library is present at positions 239 -242 in the HLA-B heavy chain ␣3 domain. These residues, with the exception of R, are also present at the same positions in the HLA-A and -C heavy chain ␣3 domains (Fig. 6) . Furthermore, for reasons which will be discussed in the next sections, it is noteworthy that the two alanine residues present at the N terminus of the pVIII major coat protein of the bacteriophage vector f88. 4 (24) are also present at positions 245 and 246 in HLA-A, -B, and -C heavy chain ␣3 domains.
Reactivity of mAb TP25.99 with the cyclic LX-8 peptides
Glutaraldehyde cross-linked cyclic LX-8 no. 1 peptide with the sequence corresponding to that present in the phage-displayed LX-8 clone reacted in binding assays with mAb TP25.99 (data not shown). Furthermore, the cyclic LX-8 no. 1 peptide inhibited the reactivity of mAb TP25.99 with ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains in a concentration-dependent fashion with an IC 50 of ϳ70 M (Fig. 7) . The inhibition is specific, as the cyclic LX-8 no. 1 peptide did not inhibit the binding of mAb CR11-351 and mAb HC-10 to HLA-A2 Ags and to ␤ 2 m-free HLA class I heavy chains, respectively. Furthermore, the control no. 7 peptide did not inhibit the binding of mAb TP25.99 to HLA class I Ags (Table III) .
The reactivity of mAb TP25.99 with the cyclic LX-8 no. 1 peptide requires the presence of disulfide bonds, because the corresponding linear LX-8 no. 1 peptide, in the presence of the reducing agent, DTT did not inhibit the binding of mAb TP25.99 to HLA class I Ags (data not shown). Furthermore mAb TP25.99 did not react with the linear LX-8 no. 1, C3 S peptide (Fig. 7) , where the cysteine residues were substituted with serine residues, precluding the formation of a disulfide bond. These results strongly suggest that mAb TP25.99 recognizes a structural motif.
Reactivity of mAb TP25.99 with the linear X 15 peptide
The synthetic linear X 15 no. 4 peptide with a sequence corresponding to the X 15 phage-displayed peptide had no detectable effect on the reactivity of mAb TP25.99 with ␤ 2 m-free and ␤ 2 m-associated HLA class I heavy chains, because the amino acids AA present at the N terminus of the pVIII major coat protein of bacteriophage vector f88.4 contribute to the expression of the determinant recognized by mAb TP25.99. The two alanine residues are also present in the HLA class I heavy chain ␣3 domain at positions 245 and 246. Therefore, a peptide was synthesized with a sequence corresponding to the linear X 15 no. 4 peptide with the addition of the amino acid residues AAEG at the C terminus. This peptide, referred to as linear X 19 no. 5 peptide, inhibited the reactivity of mAb TP25.99 with both ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains with an IC 50 of ϳ30 M (Fig. 7) . The inhibition is specific, as the linear X 19 no. 5 peptide did not inhibit the binding of mAb CR11-351 and mAb HC-10 to ␤ 2 m-associated HLA-A2 heavy chains and to ␤ 2 m-free HLA class I heavy chains, respectively. It is noteworthy that the linear X 17 no. 6 (X 19 -EG) peptide inhibited the binding of mAb TP25.99 to HLA class I Ags to the same extent as the linear X 19 no. 5 peptide (data not shown). Thus, the amino acid residues EG present in the pVIII major coat protein, at positions adjacent to the two A residues do not contribute to the expression of the determinant recognized by mAb TP25.99.
Simultaneous interaction of mAb TP25.99 with both the cyclic LX-8 no. 1 peptide and the linear X 19 no. 5 peptide
The cyclic LX-8 no. 1 peptide and the linear X 19 no. 5 peptide, which correspond to the conformational and linear determinants identified by mAb TP25.99, respectively, share no sequence homology. Hence inhibition assays were performed to determine whether the two peptides bind independently to two noninteracting binding sites on mAb TP25.99 or act concurrently and bind to the same or overlapping binding sites. As shown in Fig. 7 , combination of the cyclic LX-8 no. 1 peptide and the linear X 19 no. 5 peptide inhibited the binding of mAb TP25.99 to ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains to a lower extent than the linear X 19 no. 5 peptide and to a greater extent than the cyclic LX-8 no. 1 peptide. The inhibitory activity of the mixture of the two peptides is consistent with their differential ability to inhibit the binding of mAb TP25.99 to HLA class I Ags. Furthermore, this data is compatible with the possibility that the two peptides compete for binding to the same or spatially close binding sites on mAb TP25.99. This interpretation is supported by the dose-dependent inhibition by the linear X 19 no. 5 peptide of the reactivity of mAb TP25.99 with the cyclic LX-8 no. 1 peptide (Fig. 8) .
Discussion
The present study has shown that the anti-HLA class I mAb TP25.99 has the unique characteristic to recognize a conformational and a linear determinant on a single protein molecule. Although the conformational determinant is expressed on all known ␤ 2 m-associated HLA class I allospecificities, the linear determinant is expressed on ␤ 2 m-free HLA class I heavy chains of a subset of HLA class I allospecificities. The latter includes all those encoded by the HLA-B locus except HLA-B73 and Ͻ50% of those encoded by the HLA-A locus.
The fine specificity of the mAb TP25.99 is different from that of mAb Q1/28 (5), A1.4 (6), and 5H7 (30) , which also recognize determinants expressed both on ␤ 2 m-free and ␤ 2 m-associated HLA class I heavy chain ␣3 domains. mAb Q1/28 and 5H7 do not react with the peptides identified with mAb TP25.99 (unpublished results). Furthermore, the different effects of mAb A1.4 and mAb TP25.99 on staphylococcal enterotoxin B-induced T cell proliferation suggest that the two mAb recognize distinct, although spatially close, determinants on the HLA class I ␣3 domain (31) .
Screening anti-HLA class I mAb TP25.99 (33)) indicates that this mAb recognizes a structural motif rather than a sequence-dependent determinant. An analysis of the x-ray structure of HLA class I Ags indicates that the linear determinant is not available for binding of mAb TP25.99 to ␤ 2 m-associated HLA class I Ags, because it is masked by the ␤ 2 m. This phenomenon may account for the immunogenicity of mAb TP25.99 defined determinant in BALB/c mice, because the amino acid sequence of the linear determinant is conserved through phylogenetic evolution (34) . Furthermore, the homology of the linear and cyclic peptide sequences with two distinct areas of HLA class I ␣3 domain, strengthens the hypothesis that mAb TP25.99 recognizes two determinants independently and argues against the possibility that mAb TP25.99 recognizes a split epitope. The latter phenomenon has been reported for the CD39 B cell marker by Maliszewski et al. (35) .
One might argue that the reactivity of mAb TP25.99 with two distinct determinants of HLA class I Ags reflects the presence in the Ab preparation of two Ab populations which have the same heavy chain, but different light chains. One of them is derived from the fusing B cell and the other one from the fusing partner. This possibility is highly unlikely, because the myeloma cell line P3-X63-Ag8.653 used to generate the hybridoma TP25.99 does not express IgG heavy and light chains (36) . Furthermore, in inhibition assays the cyclic and the linear peptides isolated with mAb TP25.99 inhibit completely its reactivity with ␤ 2 m-associated and ␤ 2 m-free HLA class I heavy chains. The similar inhibitory activity of the two peptides is not compatible with the possibility that one of the two hypothesized Ab populations is present in the mAb TP25.99 preparations tested in a small amount and, therefore, has no detectable effect on the outcome of the inhibition assay. Lastly, similar results were obtained using different preparations of mAb TP25.99 prepared from batches of the hybridoma kept in culture for at least 2 mo.
To the best of our knowledge, the results of this study are unique and identify for the first time a mAb that recognizes two structurally similar cross-reactive epitopes present on the same antigenic structure. In contrast, cross-reactivity among epitopes which are similar in their amino acid sequence or in their structure, but are expressed on disparate Ags has been reported by several investigators (37-39). The latter cross-reactivity provides a molecular basis for the pathogenesis of autoimmune diseases (40) .
Panning phage display peptide libraries with mAb has previously isolated peptides that have distinct sequences from the original epitope. Despite the lack of homology with the original epitope (41) (42) (43) (44) , some of these peptides have been effective in inhibiting the corresponding Ag-Ab interaction and in eliciting an immune response. In contrast, recognition by a mAb of multiple peptides dissimilar in sequence and conformation is an infrequent finding, because, to the best of our knowledge, this has been described so far only in case of an anti-p24 HIV glycoprotein mAb. X-ray crystallographic analysis of the polyspecificity of this mAb indicates interaction of the peptides with different contact residues in the Ag-combining site of the mAb (45, 46) . Whether a similar mechanism underlies the reactivity of mAb TP25.99 with multiple peptide conformations remains to be determined.
In recent years, B and TCRs have been described to display a similar or identical specificity in a few antigenic systems (47) (48) (49) . This finding is unexpected, given the differences in the molecular basis of the recognition of an Ag by B and T cells. The latter recognize processed linear peptides presented by MHC class I Ags, while B cells recognize native folded protein conformations. Recognition by mAb TP25.99 of a similar, if not identical conformational and linear determinant on distinct amino acid stretches of the HLA class I Ag, provides an alternative molecular mechanism for the sharing of specificity by an Ab and a TCR. This mechanism may also account for the unexpected development of not only a humoral, but also a T cell immune response (50) following immunizations with multichain Ags which require the association of distinct subunits for the expression of their immunogenic moiety, such as anti-idiotypic Abs. 
